ATE213590T1 - Fgf9 als spezifischer ligand für fgfr3 - Google Patents
Fgf9 als spezifischer ligand für fgfr3Info
- Publication number
- ATE213590T1 ATE213590T1 AT96917641T AT96917641T ATE213590T1 AT E213590 T1 ATE213590 T1 AT E213590T1 AT 96917641 T AT96917641 T AT 96917641T AT 96917641 T AT96917641 T AT 96917641T AT E213590 T1 ATE213590 T1 AT E213590T1
- Authority
- AT
- Austria
- Prior art keywords
- fgfr3
- bone
- progenitor cells
- skeletal progenitor
- marker
- Prior art date
Links
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 title abstract 9
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 title abstract 9
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 title 1
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 210000000988 bone and bone Anatomy 0.000 abstract 6
- 239000003550 marker Substances 0.000 abstract 6
- 210000000130 stem cell Anatomy 0.000 abstract 6
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 2
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 239000002254 cytotoxic agent Substances 0.000 abstract 2
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 2
- 239000007943 implant Substances 0.000 abstract 2
- 230000004807 localization Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 210000001519 tissue Anatomy 0.000 abstract 2
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/50—Fibroblast growth factors [FGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13795P | 1995-06-12 | 1995-06-12 | |
| PCT/IL1996/000011 WO1996041523A1 (en) | 1995-06-12 | 1996-06-12 | Fgf9 as a specific ligand for fgfr3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE213590T1 true ATE213590T1 (de) | 2002-03-15 |
Family
ID=21690089
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96917641T ATE213590T1 (de) | 1995-06-12 | 1996-06-12 | Fgf9 als spezifischer ligand für fgfr3 |
| AT96917640T ATE225652T1 (de) | 1995-06-12 | 1996-06-12 | Fgfr3 als signal für die vorläufer der mesenchymzellen des skeletts |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96917640T ATE225652T1 (de) | 1995-06-12 | 1996-06-12 | Fgfr3 als signal für die vorläufer der mesenchymzellen des skeletts |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6447783B1 (de) |
| EP (3) | EP1342476A3 (de) |
| JP (3) | JP3673281B2 (de) |
| CN (1) | CN1195982A (de) |
| AT (2) | ATE213590T1 (de) |
| AU (2) | AU715996B2 (de) |
| CA (2) | CA2223701C (de) |
| DE (2) | DE69619526T2 (de) |
| DK (2) | DK0833620T3 (de) |
| ES (2) | ES2183957T3 (de) |
| IL (2) | IL122472A (de) |
| WO (2) | WO1996041620A1 (de) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8556983B2 (en) | 2001-05-25 | 2013-10-15 | Conformis, Inc. | Patient-adapted and improved orthopedic implants, designs and related tools |
| US8771365B2 (en) | 2009-02-25 | 2014-07-08 | Conformis, Inc. | Patient-adapted and improved orthopedic implants, designs, and related tools |
| US8480754B2 (en) | 2001-05-25 | 2013-07-09 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
| US8882847B2 (en) | 2001-05-25 | 2014-11-11 | Conformis, Inc. | Patient selectable knee joint arthroplasty devices |
| US8545569B2 (en) | 2001-05-25 | 2013-10-01 | Conformis, Inc. | Patient selectable knee arthroplasty devices |
| US8617242B2 (en) | 2001-05-25 | 2013-12-31 | Conformis, Inc. | Implant device and method for manufacture |
| US7468075B2 (en) | 2001-05-25 | 2008-12-23 | Conformis, Inc. | Methods and compositions for articular repair |
| US7618451B2 (en) | 2001-05-25 | 2009-11-17 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools facilitating increased accuracy, speed and simplicity in performing total and partial joint arthroplasty |
| US9603711B2 (en) | 2001-05-25 | 2017-03-28 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
| US7534263B2 (en) | 2001-05-25 | 2009-05-19 | Conformis, Inc. | Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty |
| US8083745B2 (en) | 2001-05-25 | 2011-12-27 | Conformis, Inc. | Surgical tools for arthroplasty |
| US8735773B2 (en) | 2007-02-14 | 2014-05-27 | Conformis, Inc. | Implant device and method for manufacture |
| US8234097B2 (en) | 2001-05-25 | 2012-07-31 | Conformis, Inc. | Automated systems for manufacturing patient-specific orthopedic implants and instrumentation |
| US6136040A (en) * | 1998-03-05 | 2000-10-24 | Washington University | Animal model with disrupted FGF-9 gene |
| US7184814B2 (en) | 1998-09-14 | 2007-02-27 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and assessing cartilage loss |
| JP2002532126A (ja) | 1998-09-14 | 2002-10-02 | スタンフォード ユニバーシティ | 関節状態の評価及び損傷防止装置 |
| US7239908B1 (en) | 1998-09-14 | 2007-07-03 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and devising treatment |
| US20020058036A1 (en) * | 1999-07-27 | 2002-05-16 | Michael Jeffers | Novel fibroblast growth factor and nucleic acids encoding same |
| US7479367B1 (en) | 1999-10-06 | 2009-01-20 | Tigenex N.V. | In vivo assay and molecular markers for testing the phenotypic stability of cell populations and selected cell populations for autologous transplantation |
| US7482114B2 (en) | 1999-10-06 | 2009-01-27 | Tigenix N.V. | In vivo assay and molecular markers for testing the phenotypic stability of cell populations, and selected cell populations for autologous transplantation |
| DE20023640U1 (de) | 1999-10-06 | 2005-06-23 | Tigenix N.V. | Isolierung von Vorläuferzellen und deren Verwendung zum Wiederaufbau von Bindegewebe |
| US20030149238A1 (en) * | 2000-02-14 | 2003-08-07 | Pankaj Agarwal | Novel compounds |
| AU2001240149A1 (en) * | 2000-03-13 | 2001-09-24 | Amgen Inc | Fibroblast growth factor-like molecules and uses thereof |
| AU9088801A (en) | 2000-09-14 | 2002-03-26 | Univ Leland Stanford Junior | Assessing the condition of a joint and devising treatment |
| CA2434881A1 (en) * | 2001-02-02 | 2002-08-15 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Method for identifying functional nucleic acids |
| US8439926B2 (en) | 2001-05-25 | 2013-05-14 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
| US8951260B2 (en) | 2001-05-25 | 2015-02-10 | Conformis, Inc. | Surgical cutting guide |
| CN100502808C (zh) | 2001-05-25 | 2009-06-24 | 肯弗默斯股份有限公司 | 用于关节表面再造的组合物 |
| EP1423428B2 (de) | 2001-06-20 | 2012-11-14 | Fibron Ltd. | Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon |
| WO2003076467A1 (en) * | 2002-03-14 | 2003-09-18 | Yeda Research And Development Co. Ltd. | Compositions and methods for inducing and regulating bone formation |
| WO2004022095A1 (en) * | 2002-09-04 | 2004-03-18 | Abtech | Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy |
| JP2006501977A (ja) | 2002-10-07 | 2006-01-19 | コンフォーミス・インコーポレイテッド | 関節表面に適合する３次元外形を伴う最小限侵襲性関節インプラント |
| JP2006505366A (ja) | 2002-11-07 | 2006-02-16 | コンフォーミス・インコーポレイテッド | 半月板サイズおよび形状の決定および工夫した処置の方法 |
| WO2006002262A2 (en) | 2004-06-21 | 2006-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder |
| AU2011211453B2 (en) * | 2004-06-21 | 2015-01-15 | The Board Of Trustees Of The Leland Stanford Junior University | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder |
| US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
| CN101506355B (zh) * | 2004-09-24 | 2012-06-27 | 成血管细胞系统公司 | 多能扩增间充质前体细胞子代（memp）及其应用 |
| US7391676B2 (en) * | 2004-12-22 | 2008-06-24 | Asml Netherlands B.V. | Ultrasonic distance sensors |
| US20060183712A1 (en) * | 2005-02-17 | 2006-08-17 | The Texas A&M University System | Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor |
| US20070049739A1 (en) * | 2005-08-30 | 2007-03-01 | Biomet Manufacturing Corp. | Method and system for extracting blood-derived growth factors |
| EP1981409B1 (de) | 2006-02-06 | 2017-01-11 | ConforMIS, Inc. | Vom patienten auswählbare gelenkarthroplastie-vorrichtungen und chirurgische instrumente |
| US8623026B2 (en) | 2006-02-06 | 2014-01-07 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief |
| CN101657536B (zh) * | 2007-01-23 | 2016-06-01 | 公立大学法人横浜市立大学 | 软骨细胞制备方法 |
| WO2009111626A2 (en) | 2008-03-05 | 2009-09-11 | Conformis, Inc. | Implants for altering wear patterns of articular surfaces |
| WO2009140294A1 (en) | 2008-05-12 | 2009-11-19 | Conformis, Inc. | Devices and methods for treatment of facet and other joints |
| US8870876B2 (en) | 2009-02-13 | 2014-10-28 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| US9017334B2 (en) | 2009-02-24 | 2015-04-28 | Microport Orthopedics Holdings Inc. | Patient specific surgical guide locator and mount |
| US8808297B2 (en) | 2009-02-24 | 2014-08-19 | Microport Orthopedics Holdings Inc. | Orthopedic surgical guide |
| US8808303B2 (en) | 2009-02-24 | 2014-08-19 | Microport Orthopedics Holdings Inc. | Orthopedic surgical guide |
| HUE025726T2 (en) | 2009-03-25 | 2016-04-28 | Genentech Inc | Anti-FGFR3 antibodies and their use |
| WO2010121147A1 (en) | 2009-04-16 | 2010-10-21 | Conformis, Inc. | Patient-specific joint arthroplasty devices for ligament repair |
| US8277459B2 (en) | 2009-09-25 | 2012-10-02 | Tarsus Medical Inc. | Methods and devices for treating a structural bone and joint deformity |
| AU2010327987B2 (en) | 2009-12-11 | 2015-04-02 | Conformis, Inc. | Patient-specific and patient-engineered orthopedic implants |
| US8652141B2 (en) | 2010-01-21 | 2014-02-18 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| US8696719B2 (en) | 2010-06-03 | 2014-04-15 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| AU2012217654B2 (en) | 2011-02-15 | 2016-09-22 | Conformis, Inc. | Patient-adapted and improved articular implants, procedures and tools to address, assess, correct, modify and/or accommodate anatomical variation and/or asymmetry |
| US9486226B2 (en) | 2012-04-18 | 2016-11-08 | Conformis, Inc. | Tibial guides, tools, and techniques for resecting the tibial plateau |
| US9675471B2 (en) | 2012-06-11 | 2017-06-13 | Conformis, Inc. | Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components |
| KR20160002681A (ko) * | 2013-01-16 | 2016-01-08 | 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) | 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드 |
| US20150216860A1 (en) | 2013-03-10 | 2015-08-06 | National University Corporation Nagoya University | Therapeutic agent for systemic bone disease and use thereof |
| MX2018016257A (es) | 2016-07-07 | 2019-11-21 | Therachon Sas | Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos. |
| EP3975939A4 (de) | 2019-05-29 | 2023-01-11 | Wright Medical Technology, Inc. | Vorbereitung eines schienbeins zur aufnahme einer schienbeinimplantatkomponente eines ersatzknöchels |
| JP2020015733A (ja) * | 2019-08-19 | 2020-01-30 | アンセルムＩｎｓｅｒｍ | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
| IT201900025126A1 (it) * | 2019-12-20 | 2021-06-20 | Sildeha Swiss S A | Uso di derivati dell’acido ialuronico nella rigenerazione dei tessuti ossei e cartilaginei |
| CN116162589A (zh) * | 2022-12-30 | 2023-05-26 | 西北工业大学 | 干细胞及其制备方法和应用、及标记组合物及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5226914A (en) * | 1990-11-16 | 1993-07-13 | Caplan Arnold I | Method for treating connective tissue disorders |
| US5270197A (en) | 1990-12-20 | 1993-12-14 | The Children's Medical Center Corporation | Cells expressing a substantial number of surface high affinity HBGF receptors but relatively few low affinity HBGF binding sites and system for assaying binding to HBGF receptor |
| JP3385040B2 (ja) * | 1991-02-14 | 2003-03-10 | 武田薬品工業株式会社 | グリア活性化因子およびその製造法 |
| EP0608546A3 (en) * | 1992-12-22 | 1995-09-27 | Takeda Chemical Industries Ltd | Glia activating factor (gaf), antibodies against it and their uses. |
| AU6446194A (en) * | 1993-03-17 | 1994-10-11 | Whittier Institute For Diabetes And Endocrinology, The | Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof |
-
1996
- 1996-06-12 DE DE69619526T patent/DE69619526T2/de not_active Expired - Lifetime
- 1996-06-12 AU AU60144/96A patent/AU715996B2/en not_active Ceased
- 1996-06-12 JP JP50286997A patent/JP3673281B2/ja not_active Expired - Lifetime
- 1996-06-12 EP EP02022340A patent/EP1342476A3/de not_active Withdrawn
- 1996-06-12 ES ES96917640T patent/ES2183957T3/es not_active Expired - Lifetime
- 1996-06-12 JP JP9502870A patent/JPH11507828A/ja not_active Ceased
- 1996-06-12 US US08/981,030 patent/US6447783B1/en not_active Expired - Lifetime
- 1996-06-12 CA CA2223701A patent/CA2223701C/en not_active Expired - Lifetime
- 1996-06-12 DK DK96917640T patent/DK0833620T3/da active
- 1996-06-12 AU AU60145/96A patent/AU721773B2/en not_active Ceased
- 1996-06-12 WO PCT/IL1996/000010 patent/WO1996041620A1/en active IP Right Grant
- 1996-06-12 CA CA002224229A patent/CA2224229A1/en not_active Abandoned
- 1996-06-12 CN CN96194719A patent/CN1195982A/zh active Pending
- 1996-06-12 WO PCT/IL1996/000011 patent/WO1996041523A1/en active IP Right Grant
- 1996-06-12 IL IL12247296A patent/IL122472A/xx not_active IP Right Cessation
- 1996-06-12 DK DK96917641T patent/DK0836380T3/da active
- 1996-06-12 ES ES96917641T patent/ES2173289T3/es not_active Expired - Lifetime
- 1996-06-12 AT AT96917641T patent/ATE213590T1/de not_active IP Right Cessation
- 1996-06-12 AT AT96917640T patent/ATE225652T1/de not_active IP Right Cessation
- 1996-06-12 EP EP96917641A patent/EP0836380B1/de not_active Expired - Lifetime
- 1996-06-12 EP EP96917640A patent/EP0833620B1/de not_active Expired - Lifetime
- 1996-06-12 IL IL12247396A patent/IL122473A/xx not_active IP Right Cessation
- 1996-06-12 DE DE69624239T patent/DE69624239T2/de not_active Expired - Fee Related
-
2002
- 2002-08-02 US US10/212,357 patent/US20020193309A1/en not_active Abandoned
-
2004
- 2004-06-29 JP JP2004192332A patent/JP2004305221A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69619526D1 (de) | Fgf9 als spezifischer ligand für fgfr3 | |
| DE69628290D1 (de) | Methoden und zusammensetzungen zur lipidisierung hydrophiler moleküle | |
| TR200000927T2 (tr) | Prostaglandin agonistleri ve kemik bozukluklarının tedavisi | |
| ATE156365T1 (de) | Osteogenische wachstumsfaktoren zur abgabe an zielorgan | |
| DE69632401D1 (de) | Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung | |
| BR0313197A (pt) | Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico | |
| ATE198980T1 (de) | Bioabbaubare polymere zur zelltransplantation | |
| HK1033582A1 (en) | Antibodies to death receptor 4 (dr4) and uses thereof | |
| IL146448A0 (en) | Dr4 antibodies and uses thereof | |
| FI954541A0 (fi) | Keratinosyyttikasvutekijän terapeuttisia käyttöjä | |
| TR199901433T2 (xx) | Pirolo$3,4-D] pirimidinon t�revleri ve bunlar�n ila� olarak kullan�mlar�. | |
| GEP20033081B (en) | Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas | |
| DK1007566T3 (da) | Terapeutisk anvendelse af SMR1-protein og aktive derivater deraf | |
| WO1999051186A3 (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders | |
| CA2069638A1 (en) | Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands | |
| ATE222122T1 (de) | Verfahren zur tötung von zielzellen in geernteten zellpopulationen mit hilfe von zwei immunotoxinen | |
| DE69737455D1 (de) | Definierte systeme zur kultivieurng epithelialer zellen und anwendung derselben | |
| PL361732A1 (en) | Use of a biological material containing three-dimensional scaffolds of hyaluronic acid derivatives for the preparation of implants in arthroscopy and kit for instruments for implanting said biological material by arthroscopy | |
| PT1150716E (pt) | Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao | |
| ATE106883T1 (de) | Azelastin-embonat, verfahren zu seiner herstellung und pharmazeutische zubereitungen, die als wirkstoff azelastin-embonat enthalten. | |
| Smart et al. | Effect of dietary ascorbate on covalent binding of benzene to bone marrow and hepatic tissue in vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REN | Ceased due to non-payment of the annual fee |